Register to view the archived recording here.
BG Medicine Aims to Raise $67M in IPO; Continues Transition from Services to Diagnostics Development
In an amended preliminary prospectus for its IPO filed this week, the company noted that it plans to apply more than half the funds raised by the offering to the development of its BGM Galectin-3, AMIPredict, and LipidDx protein biomarker products.
New to GenomeWeb? Register here quickly.